Larbcharoensub Noppadol, Wattanatranon Duangkamon, Leopairut Juvady, Suntisuktana Suwimon, Roongpupaht Boonsam, Chintrakarn Chalermchai, Tungkeeratichai Jumroon, Praneetvatakul Phurich, Bhongmakapat Thongchai, Cheewaruangroj Wichit, Prakunhungsit Supawadee
Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. E-mail:
Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2035-2042. doi: 10.22034/APJCP.2017.18.8.2035.
Objective: To evaluate the clinicopathologic findings and treatment outcome in laryngectomized patients with laryngeal cancer and hypopharyngeal cancer. Materials and Methods: The authors retrospectively reviewed the medical records of 212 patients who had been newly diagnosed and treated with laryngectomy between January 2000 and December 2010. The age, gender, clinical manifestations, associated predisposing condition, tumor WHO grade, AJCC tumor stage, maximum tumor size, anatomical involvement, type of surgery, postoperative sequelae, treatment and therapeutic outcome were analyzed. Results: The present study included laryngeal cancer (n = 155) and hypopharyngeal cancer (n = 57). The patients’ age ranged from 38 to 84 years, with the mean age of 62.08±9.67 years. The common clinical presentations were hoarseness (73.6%), cervical lymphadenopathy (35.8%), sorethroat (22.2%), and odynophagia (14.6%). The laryngeal cancer commonly involves true vocal cord (86.5%), anterior commissure (65.8%), false vocal cord (56.8%), laryngeal ventricle (53.5%), subglottis (47.1%), and paraglotic space (35.5%), respectively. Fifty-three percent of cases had stage IV cancer. The most common postoperative surgical sequela was hypothyroidism (77.8%). The overall 5-year survivals for laryngeal cancer and hypopharyngeal cancer were 55% and 9%, respectively. The 5-year survival for node-negative cases was 61.8% versus 17% for node-positive cases (p< 0.001). AJCC stage of laryngeal cancer and hypopharyngeal cancer was a significant predictor of 5-year survival (p< 0.001 and p = 0.004, respectively). Conclusions: The advanced AJCC stage, advanced T stage, advanced N stage, extracapsular tumor spread, and tumor invasion of false vocal cord, epiglottis, preepiglottic space, paraglottic space, thyroid cartilage, cricothyroid membrane were found to significantly augment the decrease of 5-year survival in laryngeal cancer. Only advanced AJCC stage was significantly associated with 5-year survival rate in hypopharyngeal cancer.
评估喉癌和下咽癌行喉切除患者的临床病理特征及治疗效果。材料与方法:作者回顾性分析了2000年1月至2010年12月期间212例新诊断并行喉切除治疗患者的病历。分析了患者的年龄、性别、临床表现、相关易感因素、肿瘤WHO分级、AJCC肿瘤分期、最大肿瘤大小、解剖受累情况、手术类型、术后后遗症、治疗及治疗效果。结果:本研究包括喉癌(n = 155)和下咽癌(n = 57)。患者年龄范围为38至84岁,平均年龄为62.08±9.67岁。常见临床表现为声音嘶哑(73.6%)、颈部淋巴结肿大(35.8%)、咽痛(22.2%)和吞咽痛(14.6%)。喉癌分别常见累及真声带(86.5%)、前联合(65.8%)、假声带(56.8%)、喉室(53.5%)、声门下区(47.1%)和甲状软骨旁间隙(35.5%)。53%的病例为IV期癌症。最常见的术后手术后遗症是甲状腺功能减退(77.8%)。喉癌和下咽癌的总体5年生存率分别为55%和9%。淋巴结阴性病例的5年生存率为61.8%,而淋巴结阳性病例为17%(p<0.001)。喉癌和下咽癌的AJCC分期是5年生存率的重要预测因素(分别为p<0.001和p = 0.004)。结论:发现AJCC分期晚期、T分期晚期、N分期晚期、肿瘤包膜外扩散以及肿瘤侵犯假声带、会厌、会厌前间隙、甲状软骨旁间隙、甲状软骨、环甲膜会显著增加喉癌5年生存率的降低。在下咽癌中,只有AJCC分期晚期与5年生存率显著相关。